Filter Results:
(123)
Show Results For
- All HBS Web
(123)
- People (1)
- News (52)
- Research (57)
- Events (1)
- Multimedia (5)
- Faculty Publications (29)
Show Results For
- All HBS Web
(123)
- People (1)
- News (52)
- Research (57)
- Events (1)
- Multimedia (5)
- Faculty Publications (29)
- 24 Aug 2020
- Blog Post
My Journey to Joining the first MS/MBA Biotechnology: Life Sciences Cohort
explore the biopharma world, so I joined L.E.K. Consulting after graduation and made my way to their Life Sciences practice. At L.E.K., I learned a tremendous amount about various pharma and biotech companies and their therapies. I worked... View Details
Gil Addo
firms and in 2021 was acquired by Oak Street Health for $190 million. Prior to founding RubiconMD, Gil was a Consultant at Putnam Associates, a pharma strategy consultancy, where he designed payer and market access strategies for fortune... View Details
Keywords: Digital Health
- 01 Mar 2016
- News
Off Script
top posts at Schering-Plough and Wyeth. Are there structural reforms that could be implemented in the drug industry to lower the market-driven price of drugs? Forcing pharma firms to invest in R&D a minimum percentage of the sales of any... View Details
Gil Addo
firms and in 2021 was acquired by Oak Street Health for $190 million. Prior to founding RubiconMD, Gil was a Consultant at Putnam Associates, a pharma strategy consultancy, where he designed payer and market access strategies for fortune... View Details
Keywords: Healthcare
- 01 Dec 2013
- News
Your Own Medicine
fibrosis treatment. Williams got into pharma by chance. After working in investment banking before and after HBS, he took a job at the consulting firm Corporate Decisions (now Oliver Wyman). One of his first clients was launching a drug... View Details
- Web
Kraft Precision Medicine Accelerator - Health Care
they need. Learn more: Landscape: Innovative Trials The Pharma Nonprofit Sweet Spot 4. Investment and Venture: Innovating investment models can help to minimize risk, redefine value, and align incentives. Learn more: Convening the... View Details
- 01 Aug 2013
- News
A Cure for Cold Storage
wins, combined with a July 2012 paper that detailed the science behind the technology, attracted attention from the likes of the Economist and National Public Radio. Soon, Schrader no longer had to cold call the pharma companies—they were... View Details
- Profile
Katy Lankester
entrepreneurial, but large enough to matter. That led me away from pharma and devices, to payer, provider and services. It also helped me identify what type of role I was interested in, because the courses exposed me to areas from... View Details
Keywords: Health Care
- 25 Jun 2020
- News
Covering All Corners
the pharmaceutical needs of emerging markets and has a strong presence in more than 40 countries throughout Africa and the Middle East-North Africa region. “We are a very purpose-driven team and believe in empowering the fight for health and wellbeing as a human... View Details
- Web
Entrepreneurship in Life Sciences - Course Catalog
exploration may include emerging opportunities in pharma & biotech, medical device & diagnostics advances, and related topics such as digital therapeutics, platform technologies, use of real-world evidence, data and computing, AI and... View Details
- 04 Feb 2019
- Blog Post
Presenting…an Alternative to Company Presentations: Evercore Grabs Attention with Interactive Events
company, Takeda acquiring Shire, a UK company. Why Takeda and Shire? “It was one of the most complex transaction we’ve worked on,” says Joseph. “As the third largest pharma M&A deal in history and the largest Japanese M&A deal in... View Details
- 09 Aug 2010
- Research & Ideas
How to Speed Up Energy Innovation
something like that in energy, which is particularly interesting in areas like conservation. Biotech and pharma are more dependent on patents than energy is likely to be; but one of the most important things we learned from looking at... View Details
- 24 May 2022
- Blog Post
Get to Know 2022 Class Day Student Speaker Peter James Kiernan
that with the immense challenges we were facing, despite our expanded emergency powers and ability to deploy resources, we couldn’t solve the problem ourselves,” said Kiernan. “We needed the private sector—manufacturers, hospitals, consultants, labs, View Details
- 01 Mar 2023
- News
The Latest Model
was booming: The price of bitcoin had surged to nearly $20,000; governments were beginning to recognize the cryptocurrency as legal tender; and industries from fintech to pharma were launching blockchain-related projects. (Though best... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
science-based research is something the heads of top biotech and pharmas learned long ago: There are few instant payoffs to please investors. Just ask Raymond Gilmartin, former chairman, president, and CEO of Merck & Co., who now... View Details
- 16 Jun 2015
- Blog Post
Military Alumna Reflects on Time at HBS
my new friends caught up on the Forum’s discussion, as well as their HBS cases that day— a LEAD case about a protagonist facing a management turnaround, a TOM case about a restaurant’s operations, and a FIN case valuing a Pharma company.... View Details
- 18 Jul 2018
- Research & Ideas
No More General Tso's? A Threat to 'Knowledge Recombination'
pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
- 31 May 2016
- First Look
May 31, 2016
https://cb.hbsp.harvard.edu/cbmp/product/516006-PDF-ENG Harvard Business School Case 316-162 Reimagining Capitalism: Towards a Theory of Change No abstract available. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/316162-PDF-ENG Harvard Business School... View Details
Keywords: Sean Silverthorne
- 16 Nov 2021
- News
Getting Back Together for Global Networking Night; Healthcare Conference Draws New Interest
pillars of health care in terms of the sectors, so we had pharma and biotech as one group, digital and IT, Investment, and then care providers,” says HBSHAA copresident Nicki MacManus (MBA 2009). “And there’s more and more interest in... View Details
Keywords: Margie Kelley
- 01 Mar 2007
- News
Daniel Vasella
years the growth rate of the vaccine industry will be between 15 and 20 percent, making it a very attractive industry. The margins are, again, not as high as in patented, branded products, but they still are quite attractive. Also, one of the reasons why big View Details